Now showing items 1-1 of 1

    • Spending on postapproval drug safety. 

      Ridley, David B; Kramer, Judith M; Tilson, Hugh H; Grabowski, Henry G; Schulman, Kevin A (Health Aff (Millwood), 2006-03)
      Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...